Loading organizations...

§ Private Profile · Morrisville, NC, USA
Bio-systems company enhancing animal health through targeted vaccination.
TARGAN is a unique blend of forward-thinking scientific and engineering experts changing the future of animal health through biological know-how and technology. We focus on integrating the right areas of expertise to create groundbreaking devices that will improve speed, accuracy, and animal welfare.
TARGAN has raised $150.0M across 4 funding rounds.
TARGAN has raised $150.0M in total across 4 funding rounds.
TARGAN has raised $150.0M in total across 4 funding rounds.
TARGAN's investors include Symbiotic Capital, Mountain Group Partners, Brian A., Stephen Murray, Justin Wright-Eakes, Merck Animal Health, Oval Park Capital.
TARGAN is a biotechnology systems company founded in 2015 (formerly Applied LifeSciences & Systems) that develops AI-driven automation for animal agriculture, focusing on poultry, livestock, and aquaculture to enhance animal health, welfare, and producer profitability.[1][2] Its core products include WingScan, an automated feather sexing system using high-speed imaging, AI, and machine learning for 98%+ accuracy at 100,000 chicks per hour, and a precision ocular vaccination system that delivers individualized vaccines to birds, replacing inefficient spray methods and reducing antibiotic use.[1][3][4] TARGAN serves poultry producers and hatcheries processing 500k to 4M birds weekly, solving labor-intensive manual processes, inconsistent vaccination, and sexing challenges amid rising global protein demand and sustainability pressures; its equipment-as-a-service model includes customization, remote monitoring, and 24/7 support.[1][4] The company shows strong growth momentum, with commercial machines deployed by 2023 after prototypes tested in real hatcheries, expanding from poultry into swine and aquaculture.[1][3]
TARGAN was founded in 2015 by Ramin Karimpour, its CEO, who identified an opportunity to apply AI, high-speed imaging, and automation from other industries to animal health, enabling "targeting animals" at an individual level for better welfare and producer economics—the name derives from this concept.[1][3][5] Based in Morrisville, North Carolina, Karimpour started by engaging poultry producers early for feedback, even without a product, to design systems fitting existing hatchery lines; this producer-led approach addressed the first challenge of automated sexing for day-old chicks.[3] Pivotal moments included patenting a sexing process in 2016, a working prototype by 2018, high-throughput testing in 2019-2020, real-hatchery trials, and commercial launch in 2023 with 98.8% accuracy.[3] This trajectory built on collaborative expertise in engineering, R&D, manufacturing, and sales, evolving from poultry focus to broader animal protein sectors.[1][2]
TARGAN rides the AgTech wave intersecting AI automation, precision livestock farming, and sustainable protein production, addressing global food demand amid population growth, climate pressures, and consumer shifts toward antibiotic-free meat.[1][2] Timing aligns with hatchery labor shortages, ethical culling reductions via accurate sexing, and regulations curbing chemicals, positioning its tech as essential for efficient, welfare-focused scaling in poultry (a $400B+ market) and beyond.[3][4] Market forces like rising meat consumption in emerging economies and investor interest in food security favor TARGAN, influencing the ecosystem by setting standards for individual-animal tech, partnering with producers for adoption, and inspiring similar innovations in livestock/aquaculture.[1][3]
TARGAN is poised to dominate automated animal health with commercial traction in poultry and pilots in swine/aquaculture, potentially capturing significant share in hatcheries via its scalable, service-based model.[1][4] Trends like AI advancements, welfare regulations, and protein demand will accelerate growth, with expansions leveraging existing imaging/vaccination IP for new species and diseases.[2][3] Its influence may evolve from niche disruptor to industry standard-setter, drawing more partnerships and funding as sustainability metrics become mandatory—echoing its origin as a producer-validated bet on targeted animal tech.[1][5]
TARGAN has raised $150.0M across 4 funding rounds. Most recently, it raised $100.0M Other Equity in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 6, 2026 | $100M Venture Round | Symbiotic Capital | — | Announced |
| May 1, 2022 | $35M Series C | Mountain Group Partners, Brian A. | Stephen Murray, Justin Wright Eakes | Announced |
| May 1, 2021 | $7M Series B | Mountain Group Partners, Merck Animal Health | Oval Park Capital | Announced |
| Mar 1, 2019 | $8M Series A | Mountain Group Partners, Merck Animal Health | Oval Park Capital | Announced |